Terms: = Thyroid cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Prognosis
44 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
3. Papillary thyroid carcinoma with aggressive fused follicular and solid growth pattern: A unique histological subtype with high-grade malignancy?
Murata SI; Matsuzaki I; Kishimoto M; Katsuki N; Onishi T; Hirokawa M; Kojima F
Pathol Int; 2023 May; 73(5):207-211. PubMed ID: 37042564
[TBL] [Abstract] [Full Text] [Related]
4. Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience.
Xu B; Lubin DJ; Dogan S; Ghossein RA; Viswanathan K
Virchows Arch; 2023 Mar; 482(3):479-491. PubMed ID: 36346459
[TBL] [Abstract] [Full Text] [Related]
5. Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity.
Chen J; Li Z; Jia X; Song W; Wu H; Zhu H; Xuan Z; Du Y; Zhu X; Song G; Dong H; Bian S; Wang S; Zhao Y; Xie H; Zheng S; Song P
Oncogene; 2022 May; 41(22):3118-3130. PubMed ID: 35477750
[TBL] [Abstract] [Full Text] [Related]
6. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract] [Full Text] [Related]
7. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract] [Full Text] [Related]
8. Whole-genome Sequencing of Follicular thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract] [Full Text] [Related]
9. [The possibility of using freely circulating DNA blood plasma in preoperative diagnosis of thyroid tumors].
Kachko VA; Vanushko VE; Platonova NM; Abrosimov AY; Tely Sheva EN; Snigireva GP
Probl Endokrinol (Mosk); 2020 Jun; 65(6):400-407. PubMed ID: 33351322
[TBL] [Abstract] [Full Text] [Related]
10. The Integrated Analyses of Driver Genes Identify Key Biomarkers in thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
11. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract] [Full Text] [Related]
12. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
13. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary thyroid cancer.
Masoodi T; Siraj AK; Siraj S; Azam S; Qadri Z; Albalawy WN; Parvathareddy SK; Al-Sobhi SS; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Thyroid; 2020 Jan; 30(1):42-56. PubMed ID: 31668133
[No Abstract] [Full Text] [Related]
14. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated thyroid cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
16. [The analysis of genetic and clinicopathologic characteristics in patients with follicular thyroid neoplasm].
Zhang J; Li Y; Lyu N; Ying JM
Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):594-598. PubMed ID: 31434450
[No Abstract] [Full Text] [Related]
17. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract] [Full Text] [Related]
18. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary thyroid cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract] [Full Text] [Related]
19. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Genetic Analysis of Follicular thyroid Carcinoma Predicts prognosis Independent of Histology.
Nicolson NG; Murtha TD; Dong W; Paulsson JO; Choi J; Barbieri AL; Brown TC; Kunstman JW; Larsson C; Prasad ML; Korah R; Lifton RP; Juhlin CC; Carling T
J Clin Endocrinol Metab; 2018 Jul; 103(7):2640-2650. PubMed ID: 29726952
[TBL] [Abstract] [Full Text] [Related]
[Next]